Next Biomedical Co.,Ltd. (KOSDAQ:389650)
South Korea · Delayed Price · Currency is KRW 41,300
+900 (2.23%)
At close: Jul 7, 2026
Next Biomedical Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Next Biomedical stock has a consensus rating of "Strong Buy" and an average price target of ₩97,667. The average 1-year stock price forecast is 136.48% higher than the current stock price, while the lowest is ₩83,000 (+100.97%) and the highest is ₩120,000 (+190.56%).
Price Target: ₩97,667 (+136.48%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Next Biomedical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 3 | 3 |
Financial Forecast
Revenue This Year
23.00B
from 16.48B
Increased by 39.59%
Revenue Next Year
37.90B
from 23.00B
Increased by 64.78%
EPS This Year
-153.00
from -38.00
EPS Next Year
557.00
from -153.00
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 23.4B | ||
| Avg | 23.0B | ||
| Low | 22.8B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 42.0% | ||
| Avg | 39.6% | ||
| Low | 38.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -153.00 | ||
| Avg | -153.00 | ||
| Low | -153.00 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |